Thursday is also the busiest biotech earnings days of the week, with Amgen ( AMGN), Celgene ( CELG), Gilead Sciences ( GILD), Alkermes ( ALKS) and United Therapeutics ( UTHR) all reporting second-quarter results. Amgen: Analysts are looking for earnings of $1.54 per share on total revenue of $4.08 billion. Worldwide Aranesp sales are expected to total $525 million in the quarter, Prolia/Xgeva sales $279 million, Enbrel sales $962 million. Celgene: Consensus earnings of $1.18 per share on total revenue of $1.35 billion, including Revlimid sales of $922 million. Gilead Sciences: Consensus earnings of 95 cents per share on total revenue of $2.29 billion, encompassing total product sales of $2.2 billion and worldwide HIV franchise sales of $1.88 billion. Alkermes: Consensus earnings estimate of 16 cents per share on total revenue of $127.5 million. United Therapeutics: Consensus earnings estimate of $1.13 per share on total revenue of $213.7 million. Also reporting second-quarter earnings on Thursday: Roche, Sanofi ( SNY) and AstraZeneca ( AXN). Friday, July 27Merck ( MRK) reports second-quarter earnings. Salix Pharmaceuticals ( SLXP) and Progenics ( PGNX): FDA approval decision for expansion of the Relistor label to include treatment of opioid-induced constipation in patients with chronic, non-cancer pain. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.